Literature DB >> 15590969

Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets.

Doron Bresler1, Jan Bruder, Klaus Mohnike, William D Fraser, Peter S N Rowe.   

Abstract

MEPE (Matrix Extracellular PhosphoglycoprotEin) expression is markedly elevated in X-linked-hypophosphatemic-rickets (HYP) and tumor-induced osteomalacia (TIO). In normal individuals, circulating serum-levels of MEPE are tightly correlated with serum-phosphorus, parathyroid hormone (PTH) and bone mineral density (BMD). Also, MEPE derived, C-terminal ASARM-peptides are candidate minhibins and/or phosphatonins. Our aims were to determine: 1. whether MEPE-ASARM-peptide(s) are abnormally elevated in HYP/hyp serum, and, 2. whether the ASARM-peptide(s) accumulate in hyp mice kidney renal-tubules. Using a specific competitive ELISA we measured a five fold increase (P=0.007) of serum ASARM-peptide(s) in human HYP patients (normal subjects 3.25 microM n=9; S.E.M.=0.51 and HYP-patients 15.74 microM, n=9; S.E.M.=3.32). A 6.23 fold increase (P=0.008) was measured in hyp male mice compared with their normal male siblings (normal-siblings, 3.73 muM, S.E.M.=0.57, n=3; and hyp-mice 23.4 microM, n=3, S.E.M.=4.01). Renal immuno-histological screening also revealed a dramatic increase of ASARM-peptides in regions anatomically consistent with the proximal convoluted tubules. This study demonstrates for the first time that markedly elevated serum levels of protease-resistant ASARM-peptide(s) occur in HYP/hyp and they accumulate in murine hyp kidneys. These peptides are thus likely responsible for the phosphaturia and defective mineralization in HYP/hyp and TIO.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15590969      PMCID: PMC3357083          DOI: 10.1677/joe.1.05989

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  42 in total

1.  A peptide that inhibits hydroxyapatite growth is in an extended conformation on the crystal surface.

Authors:  J R Long; J L Dindot; H Zebroski; S Kiihne; R H Clark; A A Campbell; P S Stayton; G P Drobny
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

2.  Coordinated maturational regulation of PHEX and renal phosphate transport inhibitory activity: evidence for the pathophysiological role of PHEX in X-linked hypophosphatemia.

Authors:  T Nesbitt; I Fujiwara; R Thomas; Z S Xiao; L D Quarles; M K Drezner
Journal:  J Bone Miner Res       Date:  1999-12       Impact factor: 6.741

3.  Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP).

Authors:  Peter S N Rowe; Ian R Garrett; Patricia M Schwarz; David L Carnes; Eileen M Lafer; Gregory R Mundy; Gloria E Gutierrez
Journal:  Bone       Date:  2004-11-24       Impact factor: 4.398

4.  Pex gene deletions in Gy and Hyp mice provide mouse models for X-linked hypophosphatemia.

Authors:  T M Strom; F Francis; B Lorenz; A Böddrich; M J Econs; H Lehrach; T Meitinger
Journal:  Hum Mol Genet       Date:  1997-02       Impact factor: 6.150

5.  Identification of osteoblast/osteocyte factor 45 (OF45), a bone-specific cDNA encoding an RGD-containing protein that is highly expressed in osteoblasts and osteocytes.

Authors:  D N Petersen; G T Tkalcevic; A L Mansolf; R Rivera-Gonzalez; T A Brown
Journal:  J Biol Chem       Date:  2000-11-17       Impact factor: 5.157

6.  Characteristics of tumor cell bioactivity in oncogenic osteomalacia.

Authors:  A E Nelson; H J Namkung; J Patava; M R Wilkinson; A C Chang; R R Reddel; B G Robinson; R S Mason
Journal:  Mol Cell Endocrinol       Date:  1996-11-29       Impact factor: 4.102

7.  MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia.

Authors:  P S Rowe; P A de Zoysa; R Dong; H R Wang; K E White; M J Econs; C L Oudet
Journal:  Genomics       Date:  2000-07-01       Impact factor: 5.736

Review 8.  The role of the PHEX gene (PEX) in families with X-linked hypophosphataemic rickets.

Authors:  P S Rowe
Journal:  Curr Opin Nephrol Hypertens       Date:  1998-07       Impact factor: 2.894

9.  Distribution of mutations in the PEX gene in families with X-linked hypophosphataemic rickets (HYP).

Authors:  P S Rowe; C L Oudet; F Francis; C Sinding; S Pannetier; M J Econs; T M Strom; T Meitinger; M Garabedian; A David; M A Macher; E Questiaux; E Popowska; E Pronicka; A P Read; A Mokrzycki; F H Glorieux; M K Drezner; A Hanauer; H Lehrach; J N Goulding; J L O'Riordan
Journal:  Hum Mol Genet       Date:  1997-04       Impact factor: 6.150

10.  Intrinsic mineralization defect in Hyp mouse osteoblasts.

Authors:  Z S Xiao; M Crenshaw; R Guo; T Nesbitt; M K Drezner; L D Quarles
Journal:  Am J Physiol       Date:  1998-10
View more
  41 in total

1.  1,25-Dihydroxyvitamin D Alone Improves Skeletal Growth, Microarchitecture, and Strength in a Murine Model of XLH, Despite Enhanced FGF23 Expression.

Authors:  Eva S Liu; Janaina S Martins; Adalbert Raimann; Byongsoo Timothy Chae; Daniel J Brooks; Vanda Jorgetti; Mary L Bouxsein; Marie B Demay
Journal:  J Bone Miner Res       Date:  2016-02-02       Impact factor: 6.741

Review 2.  Role of prostaglandins in the pathogenesis of X-linked hypophosphatemia.

Authors:  Michel Baum; Ashu Syal; Raymond Quigley; Mouin Seikaly
Journal:  Pediatr Nephrol       Date:  2006-05-24       Impact factor: 3.714

3.  Identification of novel regulators of osteoblast matrix mineralization by time series transcriptional profiling.

Authors:  Katherine Ann Staines; Dongxing Zhu; Colin Farquharson; Vicky Elizabeth MacRae
Journal:  J Bone Miner Metab       Date:  2013-08-08       Impact factor: 2.626

4.  MEPE expression in osteocytes during orthodontic tooth movement.

Authors:  J Gluhak-Heinrich; D Pavlin; W Yang; M MacDougall; S E Harris
Journal:  Arch Oral Biol       Date:  2007-01-31       Impact factor: 2.633

5.  Matrix extracellular phosphoglycoprotein is expressed in causative tumors of oncogenic osteomalacia.

Authors:  Yasuo Imanishi; Jun Hashimoto; Wataru Ando; Keisuke Kobayashi; Takafumi Ueda; Yuki Nagata; Akimitsu Miyauchi; Hajime M Koyano; Hiroshi Kaji; Takatoshi Saito; Koichi Oba; Yasato Komatsu; Tomoaki Morioka; Katsuhito Mori; Takami Miki; Masaaki Inaba
Journal:  J Bone Miner Metab       Date:  2011-07-08       Impact factor: 2.626

6.  Advancing our understanding of osteocyte cell biology.

Authors:  Dayong Guo; Lynda F Bonewald
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-04       Impact factor: 5.346

Review 7.  The osteocyte: an endocrine cell ... and more.

Authors:  Sarah L Dallas; Matthew Prideaux; Lynda F Bonewald
Journal:  Endocr Rev       Date:  2013-04-23       Impact factor: 19.871

8.  Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity.

Authors:  Shiguang Liu; Peter S N Rowe; Luke Vierthaler; Jianping Zhou; L Darryl Quarles
Journal:  J Endocrinol       Date:  2007-01       Impact factor: 4.286

9.  Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP.

Authors:  Aline Martin; Valentin David; Jennifer S Laurence; Patricia M Schwarz; Eileen M Lafer; Anne-Marie Hedge; Peter S N Rowe
Journal:  Endocrinology       Date:  2007-12-27       Impact factor: 4.736

10.  Expression and processing of small integrin-binding ligand N-linked glycoproteins in mouse odontoblastic cells.

Authors:  Shuo Chen; Lei Chen; Allen Jahangiri; Bo Chen; Yimin Wu; Hui-Hsiu Chuang; Chunlin Qin; Mary MacDougall
Journal:  Arch Oral Biol       Date:  2008-06-26       Impact factor: 2.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.